Archives for March 2011

Engage with independent insights, opinions, and analysis from an array of leaders in cardiology.
Avatar of Eric Jose Velazquez, MD

ACC Preview: A STICH in Time (30 Mar 2011)

Eric Jose Velazquez, MD

Eric Velazquez is the principal investigator of the STICH (Surgical Treatment for Ischemic Heart Failure) trial. He will present the main results of the trial at the Late’Breaking Clinical Trials II session on Monday morning. Velazquez relates the origins of STICH more than a decade ago and discusses some of the fascinating challenges of completing such a unique trial. ________________________________________________ Next week, I will present results of the Surgical Revascularization Hypothesis of the Surgical Treatment for Ischemic Heart Failure, or STICH, trial at the ACC. The trial’s origins go back more than… Continue Reading

Avatar of John Mandrola, MD, FACC

The Best Tool for Treating Atrial Fibrillation (25 Mar 2011)

John Mandrola, MD, FACC

John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog, Dr John M. Today, I would like to tell you about the most effective way to treat the most common heart ailment — atrial fibrillation (AF). It’s not the novel new blood-thinner, dabigatran (Pradaxa). Though it’s obvious that preventing stroke without using a rat poison represents a huge advance. It’s not burning the left atrium with an ablation catheter. Though it’s clearly true that we can ablate AF much… Continue Reading

Avatar of Larry Husten, PHD

Legislating CVD Screening Tests in Texas (4 Mar 2011)

Amit Khera, MD, MSc

Imaging tests for cardiovascular risk assessment hold great promise.  Both coronary artery calcium (CAC) scanning and carotid intima-media thickness (CIMT) testing have been shown in multiple prospective studies to predict cardiovascular outcomes and, more recently, to improve risk reclassification based upon the Framingham Risk Score.  Coupled with frustrations about the performance of the Framingham Risk Score as well as the movement towards personalized medicine, it is understandable why there is great enthusiasm for broader implementation of these tests.  This enthusiasm has taken tangible form in the Texas Atherosclerosis Imaging Bill,… Continue Reading

Avatar of Anju Nohria, MD

Questioning the DOSE (2 Mar 2011)

Anju Nohria, MD

Although widely used for decades, the best way to use loop diuretics in patients with acute decompensated heart failure (ADHF) has never been well studied. The Diuretic Optimization Strategies Evaluation (DOSE) study, published in the New England Journal of Medicine, randomized 308 ADHF patients to a bolus every 12 hours or a continuous infusion of furosemide at either a high or low dose. No significant differences were observed in either patient symptoms or the change in creatine from baseline to 72 hours. In an accompanying editorial, Gregg Fonarow writes that the study… Continue Reading